Beetroot fight cancer with the minerals and nutrients

Beets are known to break up cancers and tumors, and they're known to do so faster than the body can eliminate them.

Because beets can break up tumors so rapidly, it's wise to combine this therapy with other detoxification methods, like colon and liver cleansing, to help your body dispose of the waste released when cancers are broken down.

…In the 1950’s, Dr. Ferenczi of Csoma, Hungary used beets exclusively to break up tumors in the body. He had considerable success, and tumors were often completely eliminated. However, he found if patients stopped drinking quantities of beet juice, tumors often reappeared. Dr. Ferenczi recommended drinking about a quarter gallon (2.2 lbs*) of beet juice daily to break up tumors, and results were often seen in a few weeks or months…

...The key cancer fighting ingredient in beets is called betacyanin; it’s what gives red beets their bright purple reddish color. Beets have also been found to increase detoxifying compounds in the body and make it easier for the body to detoxify itself in general. This, of course, adds to health…

Beets weigh about 1.5 to 2.5 pounds each – so I think this means you would make a diluted drink with the juice of 1-2 beets (2.2 pounds) and consume that daily to use this as a cancer cure protocol. WORK UP TO IT GRADUALLY. Give your body a chance to adjust to the cleansing power of the beets, and their ability to dissolve tumors.

When the Betain pigment in beets is absorbed into the blood it can reportedly increase the oxygen-carrying ability of the blood by up to 400 per cent.

Epidiolex CBD alternative to Cannabis whole plant

Epidiolex, a CBD investigational isolate produced by GW Pharmaceuticals, seems to work well in trials on seizure disorders. However, many patients already using whole-plant cannabis oil are resistant to change and say they would not switch to the isolate when and if it becomes available in the US. They do not want to change from something that is working well to a product than may or may not be effective for their needs.

A 2015 article published in the journal Pharmacology and Pharmacy [2] looked at the bell-shaped dose response seen in purified CBD extracts. The abstract states: “In stark contrast to purified CBD, the clone 202 extract (standardized plant extracts derived from Cannabis sativa), when given either intraperitoneally or orally, provided a clear correlation between the anti‐inflammatory and anti‐nociceptive responses. The dose, with increasing responses upon increasing doses, makes this plant medicine ideal for clinical uses. It is likely that other components in the extract synergize with CBD to achieve the desired anti‐inflammatory action that may contribute to overcoming the bell‐shaped dose‐response of purified CBD. We therefore propose that Cannabis clone 202 extract is superior over CBD for the treatment of inflammatory conditions.”

We still do not know all the medicinal ingredients or qualities of the cannabis plant. Essential synergy and small-but-powerful chemicals yet unidentified may significantly affect therapeutic qualities. Meanwhile, a cultural bias exists. Long-time cannabis users are generally faithful to whole plant medicine, while patients previously naïve to cannabis may prefer isolates in more traditional medication formulations such as capsules and tinctures.

What we need are controlled studies that compare the two philosophies of producing medicine from the cannabis plant. We may find that some conditions do respond to whole-plant medicine more effectively than isolates while others may be treated well with purified forms of cannabinoids. Again, patient response may vary from one formulation to another, creating even more variables to take into account.

Let’s ask and answer this one. It’s time.

Whole Plant vs. Isolate, Cannabis vs. Cannabinoid

To use the whole plant and all it has to offer, or to isolate the known active ingredients and package them as medicine? This is becoming a valid question as the medical cannabis industry grows.

HAWAIIANETHOS.COM

Brain Cancer treatment from Dr Burzynski

Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.
Burzynski SR, et al. Integr Cancer Ther. 2004.
Show full citation
Abstract
Recurrent diffuse intrinsic brain stem glioblastoma multiforme carries an extremely poor prognosis and a median survival of less than 7 months. In this article, the authors report good results in a 40-year-old man diagnosed with glioblastoma multiforme who received antineoplastons. The patient's brain tumor was diagnosed in May 1999, and he subsequently underwent subtotal tumor resection and standard radiation therapy. Magnetic resonance imaging and positron emission tomography scans documented his tumor recurrence. Approximately 2 months after completion of radiation therapy, he was admitted for administration of intravenous antineoplastons A10 and AS2-1 through a subclavian venous catheter by intermittent bolus injections 6 times per day using a portable pump. Administration of antineoplastons A10 and AS2-1 was over 655 consecutive days with the exception of a few short interruptions. The maximum dosage of A10 was 8.15 g/kg/d and AS2-1 0.35 g/kg/d. Antineoplastons A10 and AS2-1 administration was very well tolerated with only mild reversible side effects. Follow-up magnetic resonance imaging and positron emission tomography scans revealed decrease and eventually disappearance of the tumor. A complete response was documented after approximately 1 year of antineoplastons A10 and AS2-1 administration. More than 4 years later, off antineoplastons A10 and AS2-1, the patient is tumor free, able to carry on normal activities, and works full-time, and his Karnofsky Performance Status increased from 50 to 100. Extensive phase II trials with antineoplastons A10 and AS2-1 in patients with glioblastoma multiforme are nearing completion. These trials may provide more data regarding the efficacy of antineoplastons A10 and AS2-1 in the treatment of glioblastoma multiforme in untreated patients compared to the results in those patients with tumor recurrence after radiation therapy.

PMID 15312271 [PubMed - indexed for MEDLINE]
Full text
Full text at journal site
Similar articles

Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.
Clinical trial
Burzynski SR, et al. Integr Cancer Ther. 2006.
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma.
Clinical trial
Buckner JC, et al. Mayo Clin Proc. 1999.
Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.
Clinical trial
Burzynski SR, et al. Drugs R D. 20

Cancer Research- 1948 Lincoln Foundation

In 1948 the Lincoln Foundation in Massachussetts was running a trial for chronic sinus problems using some kind of a nose spray. Something unusual happened. Several of the trial participants also had cancer. Their cancers improved dramatically and some became CANCER FREE. One of those people was Senator Charles Tobey's grown son. Afterwards Tobey and his son called at least 100 AMA researchers to say take a look at this treatment. THEY ALL REFUSED. Then AMA president Morris Fishbein launched a harassment campaign against Lincoln Foundation eventually leading to it's closing. Senator Tobey launched an investigation of the AMA in regards to cancer research which later became the 1953 FitzGerald Report. Today thanks to the AMA the nose spray contents are not known.

"The AMA has participated in a conspiracy to restrain competition. The AMA has restricted, blocked, and in some cases ELIMINATED new forms of healthcare".---1980 U.S.Appeals Court Judge

History exposes Herbal formula that worked

In 1934, the University of Southern California appointed a Special Medical Research Committee to bring terminal cancer patients from Pasadena County Hospital to Rife's San Diego Laboratory and clinic for treatment. The team included doctors and pathologists assigned to examine the patients - if still alive - in 90 days.

After the 90 days of treatment, the Committee concluded that 86.5% of the patients had been completely cured. The treatment was then adjusted and the remaining 13.5% of the patients also responded within the next four weeks. The total recovery rate using Rife's technology was 100%.

On November 20, 1931, forty-four of the nation's most respected medical authorities honored Royal Rife with a banquet billed as The End To All Diseases at the Pasadena estate of Dr. Milbank Johnson.

But by 1939, almost all of these distinguished doctors and scientists were denying that they had ever met Rife. What happened to make so many brilliant men have complete memory lapses? It seems that news of Rife's miracles with terminal patients had reached other ears. Remember our hypothetical question at the beginning of this report: What would happen if you discovered a cure for everything? You are now about to find out....

At first, a token attempt was made to buy out Rife. Morris Fishbein, who had acquired the entire stock of the American Medical Association by 1934, sent an attorney to Rife with 'an offer you can't refuse.' Rife refused. We many never know the exact terms of this offer. But we do know the terms of the offer Fishbein made to Harry Hoxsey for control of his herbal cancer remedy. Fishbein's associates would receive all profits for nine years and Hoxey would receive nothing. Then, if they were satisfied that it worked, Hoxsey would begin to receive 10% of the profits. Hoxsey decided that he would rather continue to make all the profits himself. When Hoxsey turned Fishbein down, Fishbein used his immensely powerfulpolitical connections to have Hoxsey arrested 125 times in a period of 16 months. The charges (based on practice without a license) were always thrown out of court, but the harassment drove Hoxsey insane.

Royal Raymond Rife